| 查看: 2484 | 回复: 12 | ||||
[求助]
求助来那替尼上市信息？ 已有1人参与
|
||||
| 在网上看到有公司挂来那替尼项目合作信息，在CDE上有来那替尼片的进口申请，但是我却查不到该药的具体上市信息，特此求助，望大侠相帮，谢谢！ |
回复此楼» 收录本帖的淘帖专辑推荐
 颛顼药学 |
» 猜你喜欢
求购时间长一些的硝酸钍
已经有0人回复
-
博导推荐
已经有2人回复
-
药理学论文润色/翻译怎么收费?
已经有300人回复
-
哪里做甘氨酸受体与配体结合率的试验
已经有0人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学、药学和生物学等专业的研究生
已经有7人回复
-
[学习资料分享] FAERS数据库的不良反应挖掘(频数法/贝叶斯法)
已经有1人回复
-
招收医学、基础医学类调剂研究生
已经有0人回复
-
是否属于脾肾阳虚证
已经有0人回复
-
关于SCI杂志发表挂名
已经有32人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学相关专业的调剂研究生
已经有2人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 求助阿法替尼合成文献
已经有7人回复
- 【求助】FDA2012年批准新药阿西替尼的专利
已经有7人回复
- 达沙替尼上市时间？
已经有8人回复
- canertinib卡奈替尼这个抗肿瘤药物有没有上市？
已经有4人回复
- 求助奥拉西坦国外上市信息
已经有5人回复
- 【求助】凡德他尼（vandetanib）的上市国家和时间及其专利情况
已经有3人回复
- 【求助】请问不在美国上市的药物可以到什么地方查到药品研发信息？以及专利？
已经有5人回复
- 【求助】国外上市药品的信息
已经有14人回复
- 【求助】如何查日本上市的药物信息
已经有3人回复
- 【求助】伊马替尼的质量标准
已经有8人回复
- 【求助】如何寻找多肽上市药物？有哪些网站？
已经有11人回复
酔欲陶然
木虫 (正式写手)
- 应助: 7 (幼儿园)
- 金币: 3995.6
- 散金: 25
- 帖子: 345
- 在线: 263.5小时
- 虫号: 855206
- 注册: 2009-09-23
- 性别: GG
- 专业: 合成药物化学
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
5楼2014-08-28 09:04:03
6楼2014-08-28 09:30:07
9楼2014-08-28 14:11:11
2楼2014-08-27 16:55:56
3楼2014-08-27 16:58:18
4楼2014-08-28 08:46:35
7楼2014-08-28 11:20:00
8楼2014-08-28 11:22:08
|
Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014 |
10楼2014-08-28 18:00:06
